MX2022002433A - Análogos de compstatina y sus usos médicos. - Google Patents

Análogos de compstatina y sus usos médicos.

Info

Publication number
MX2022002433A
MX2022002433A MX2022002433A MX2022002433A MX2022002433A MX 2022002433 A MX2022002433 A MX 2022002433A MX 2022002433 A MX2022002433 A MX 2022002433A MX 2022002433 A MX2022002433 A MX 2022002433A MX 2022002433 A MX2022002433 A MX 2022002433A
Authority
MX
Mexico
Prior art keywords
compstatin
analogues
introduction
complement
inhibiting activity
Prior art date
Application number
MX2022002433A
Other languages
English (en)
Spanish (es)
Inventor
Anne Pernille Tofteng Shelton
Henrik Fischer Munch
Original Assignee
Zp Spv 3 K/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zp Spv 3 K/S filed Critical Zp Spv 3 K/S
Publication of MX2022002433A publication Critical patent/MX2022002433A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
MX2022002433A 2019-08-27 2020-08-26 Análogos de compstatina y sus usos médicos. MX2022002433A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19193925 2019-08-27
EP20172189 2020-04-29
PCT/EP2020/073905 WO2021037942A1 (en) 2019-08-27 2020-08-26 Compstatin analogues and their medical uses

Publications (1)

Publication Number Publication Date
MX2022002433A true MX2022002433A (es) 2022-05-19

Family

ID=72178552

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002433A MX2022002433A (es) 2019-08-27 2020-08-26 Análogos de compstatina y sus usos médicos.

Country Status (14)

Country Link
US (1) US20220306695A1 (https=)
EP (2) EP4021921A1 (https=)
JP (1) JP7711044B2 (https=)
KR (1) KR20220066287A (https=)
CN (1) CN114630836A (https=)
AU (1) AU2020338688A1 (https=)
BR (1) BR112022003760A2 (https=)
CA (1) CA3148536A1 (https=)
CO (1) CO2022003556A2 (https=)
ES (1) ES3049784T3 (https=)
IL (1) IL290858A (https=)
MX (1) MX2022002433A (https=)
TW (1) TW202128731A (https=)
WO (1) WO2021037942A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2020128624A (ru) 2018-02-27 2022-03-28 Зп Спв 3 К/С Аналоги компстатина и их медицинское применение
IL299870A (en) * 2020-07-16 2023-03-01 Zp Spv 3 K/S Complement factor C3 inhibitors and their medical uses
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
WO2023048151A1 (ja) * 2021-09-22 2023-03-30 塩野義製薬株式会社 ウイルス増殖阻害活性を有する環状ペプチド
CN120359233A (zh) * 2022-11-24 2025-07-22 阿麦达斯制药美国有限责任公司 用于基于载体的疗法的坎普他汀类似物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319897B1 (en) 1996-03-13 2001-11-20 John D. Lambris Peptides which inhibit complement activation
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
AU723268B2 (en) 1996-09-09 2000-08-24 Zealand Pharma A/S Improved solid-phase peptide synthesis and agent for use in such synthesis
WO1999013899A1 (en) 1997-09-17 1999-03-25 Trustees Of The University Of Pennsylvania Peptides and peptidomimetics for inhibiting complement activation
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
CZ20013018A3 (cs) 1999-03-17 2002-02-13 Novo Nordisk A/S Způsob pro acylování aminoskupiny peptidu nebo proteinu a sloučenina
PT1549333E (pt) 2002-09-20 2012-01-03 Univ Pennsylvania Análogos de compstatina com actividade melhorada
EP2662089A3 (en) 2005-10-08 2014-02-19 Potentia Pharmaceuticals, Inc. Compstatin and analogs thereof for eye disorders
CN102977191B (zh) 2005-11-28 2016-08-10 宾夕法尼亚州大学理事会 有效的c3补体抑制素类似物
WO2008153963A1 (en) 2007-06-08 2008-12-18 The Trustees Of The University Of Pennsylvania Structure of compstatin-c3 complex and use for rational drug design
EP2340028B1 (en) * 2008-09-30 2018-06-27 The Trustees Of The University Of Pennsylvania Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors
CA2813049A1 (en) 2010-09-23 2012-03-29 The Trustees Of The University Of Pennsylvania Modified compstatin with improved stability and binding properties
CA2847862C (en) 2011-09-07 2021-01-12 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved pharmacokinetic properties
US9512180B2 (en) 2012-12-19 2016-12-06 The Regents Of The University Of California Compstatin analogs
AR099569A1 (es) * 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
US20180057538A1 (en) * 2016-08-26 2018-03-01 The Regents Of The University Of California Potent and highly soluble pegylated compstatin peptides
RU2020128624A (ru) * 2018-02-27 2022-03-28 Зп Спв 3 К/С Аналоги компстатина и их медицинское применение

Also Published As

Publication number Publication date
AU2020338688A1 (en) 2022-03-24
KR20220066287A (ko) 2022-05-24
CO2022003556A2 (es) 2022-05-20
CN114630836A (zh) 2022-06-14
IL290858A (en) 2022-04-01
WO2021037942A1 (en) 2021-03-04
JP2022545916A (ja) 2022-11-01
TW202128731A (zh) 2021-08-01
US20220306695A1 (en) 2022-09-29
EP4021921A1 (en) 2022-07-06
BR112022003760A2 (pt) 2022-05-31
ES3049784T3 (en) 2025-12-18
EP4272751B1 (en) 2025-09-24
EP4272751A2 (en) 2023-11-08
EP4272751C0 (en) 2025-09-24
CA3148536A1 (en) 2021-03-04
JP7711044B2 (ja) 2025-07-22
EP4272751A3 (en) 2024-02-14

Similar Documents

Publication Publication Date Title
MX2022002433A (es) Análogos de compstatina y sus usos médicos.
MX2020008902A (es) Analogos de compstatina y sus usos medicos.
BRPI0811320A2 (pt) Surfactantes reconstituídos com propriedades melhoradas
EA201100038A1 (ru) Коагонисты глюкагонового рецептора/glp-1-рецептора
BRPI0620806B8 (pt) complexo e composição compreendendo um peptídeo e uma molécula carga, e uso da referida composição
DK2162462T3 (da) Cxc-chemokin-receptor-4 (cxcr4) antagonistisk polypeptid
CY1123997T1 (el) Νεα μεταλλακτικη παραλλαγη αλβουμινης ανθρωπινου ορου
MX2023000679A (es) Inhibidores del factor c3 del complemento y sus usos medicos.
MX377692B (es) Peptidos anti-inflamatorios y usos de los mismos.
RU2015101697A (ru) Аналоги глюкагона, обладающие активностью рецептора gip
NZ628987A (en) Extended recombinant polypeptides and compositions comprising same
BR112022012057A2 (pt) Novos métodos de entrega celular
NO20081654L (no) Stabiliserte GLP-1-analoger
MX2022007881A (es) Proteina f mutante del virus sincitial respiratorio (rsv) y usos de la misma.
NO20070296L (no) Oligomere peptider og deres anvendelse for behandling av HIV infeksjoner
MX2021001507A (es) Farmaco de diagnostico y metodo de diagnostico para la enfermedad de alzheimer.
BR112018013246A2 (pt) rótulo de peptídeo e proteína rotulada incluindo o mesmo
MX2019013801A (es) Compuestos de citocina inhibidora de macrofagos-1 (mic-1) y usos de estos.
JP2016516734A5 (https=)
MX2020010520A (es) Analogos de compstatina con mayor solubilidad y mejores propiedades farmacocineticas.
WO2015110809A3 (en) Drug delivery system
ATE551353T1 (de) Protein mit fusogener wirkung, nukleinsäuresequenzen, die für dieses protein codieren und pharmazeutische zusammensetzungen, die dieses enthalten
BR112022005782A2 (pt) Proteína galectina 9 estabilizada recombinante, vetor recombinante, transformante, composição farmacêutica para prevenção ou tratamento de uma doença óssea, alimento funcional de saúde para prevenção ou melhora de uma doença óssea, e, uso de uma proteína galectina 9 estabilizada recombinante
NZ706202A (en) Peptide antagonists of the vasopressin-2 receptor
EP4403566A3 (en) Peptides with vasodilatory and/or diuretic functions